A share price of Travere Therapeutics Inc [TVTX] is currently trading at $18.37, up 2.74%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TVTX shares have gain 2.23% over the last week, with a monthly amount glided 31.31%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 21, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $27 from $9. On September 09, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $25 on the stock. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to a Buy and raised its price target to $10 on December 05, 2023. Citigroup started tracking with a Neutral rating for this stock on November 20, 2023, and assigned it a price target of $7. In a note dated September 22, 2023, Wells Fargo downgraded an Equal Weight rating on this stock and revised its target price from $24 to $8.
Travere Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.12 and $19.25. Currently, Wall Street analysts expect the stock to reach $21.38 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $18.37 at the most recent close of the market. An investor can expect a potential return of 16.39% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Trailing Twelve Months sales for Travere Therapeutics Inc [NASDAQ:TVTX] were 177.64M which represents -9.35% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -2.16%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -1.02 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 25.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.77 points at the first support level, and at 17.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.68, and for the 2nd resistance point, it is at 19.00.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Travere Therapeutics Inc [NASDAQ:TVTX] is 3.04. Also, the Quick Ratio is 2.99, while the Cash Ratio stands at 0.27. Considering the valuation of this stock, the price to sales ratio is 7.91, the price to book ratio is 92.73.
Transactions by insiders
Recent insider trading involved LYONS GARY A, Director, that happened on Oct 04 ’24 when 40000.0 shares were sold. Officer, GARY A LYONS completed a deal on Oct 04 ’24 to buy 40000.0 shares. Meanwhile, Director Meckler Jeffrey A sold 40000.0 shares on Sep 30 ’24.
